Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases

Gene

Volumn 567, Issue 1, 2015, Pages 1-11

  Shagisultanova, Elena ^a   Gaponova, Anna V ^a   Gabbasov, Rashid ^a,b   Nicolas, Emmanuelle ^a   Golemis, Erica A ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

CAS family protein; CAS L; HEF1; Human malignancy; NEDD9; Prognosis; Protein function; Signal transduction

Indexed keywords

NEDD9 PROTEIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; NEDD9 PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

BREAST CANCER; CANCER THERAPY; CEREBROVASCULAR ACCIDENT; HUMAN; KIDNEY POLYCYSTIC DISEASE; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; GENETICS; NEOPLASM; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; HUMANS; NEOPLASMS; PHOSPHOPROTEINS; POLYCYSTIC KIDNEY DISEASES; STROKE;

EID: 84930484566     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.04.086     Document Type: Review

References (120)

1. Aquino J.B., et al. Differential expression and dynamic changes of murine NEDD9 in progenitor cells of diverse tissues. Gene Expr. Patterns 2008, 8(4):217-226.
2. Astier A., et al. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk. Lymphoma 1997, 28(1-2):65-72.
3. Baquiran J.B., Bradbury P., O'Neill G.M. Tyrosine Y189 in the substrate domain of the adhesion docking protein NEDD9 is conserved with p130Cas Y253 and regulates NEDD9-mediated migration and focal adhesion dynamics. PLoS One 2013, 8(7):e69304.
4. Bastian B.C., et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998, 58(10):2170-2175.
5. Beck T., Nicolas E., Kopp M., Golemis E. Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease. Oncoscience 2014, 1(7):486-503.
6. Bradbury P., Fabry B., O'Neill G.M. Occupy tissue: the movement in cancer metastasis. Cell Adh. Migr. 2012, 6(5):424-432.
7. Bradbury P., et al. PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9. Biochim. Biophys. Acta 2012, 1823(2):290-297.
8. Bradshaw L.N., et al. Estradiol stabilizes the 105-kDa phospho-form of the adhesion docking protein NEDD9 and suppresses NEDD9-dependent cell spreading in breast cancer cells. Biochim. Biophys. Acta 2011, 1813(2):340-345.
9. Briknarova K., et al. The serine-rich domain from Crk-associated substrate (p130cas) is a four-helix bundle. J. Biol. Chem. 2005, 280(23):21908-21914.
10. Bruna A., et al. TGFbeta induces the formation of tumour-initiating cells in claudinlow breast cancer. Nat. Commun. 2012, 3:1055.
11. Bui L.C., et al. Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Oncogene 2009, 28(41):3642-3651.
12. Cabodi S., et al. Integrin signalling adaptors: not only figurants in the cancer story. Nat. Rev. Cancer 2010, 10(12):858-870.
13. Cai D., et al. The GDP exchange factor AND-34 is expressed in B cells, associates with HEF1, and activates Cdc42. J. Immunol. 2003, 170(2):969-978.
14. Carretero J., et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010, 17(6):547-559.
15. Chang J.X., et al. Role of NEDD9 in invasion and metastasis of lung adenocarcinoma. Exp. Ther. Med. 2012, 4(5):795-800.
16. Chapuis J., et al. Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease. Hum. Mol. Genet. 2008, 17(18):2863-2867.
17. Chen L., et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013, 23(6):826-838.
18. Dadke D., et al. Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle. Mol. Biol. Cell 2006, 17(3):1204-1217.
19. de Jong R., et al. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl. J. Biol. Chem. 1997, 272(51):32649-32655.
20. Dilworth S.M. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat. Rev. Cancer 2002, 2(12):951-956.
21. Fashena S.J., et al. Dissection of HEF1-dependent functions in motility and transcriptional regulation. J. Cell Sci. 2002, 115(Pt 1):99-111.
22. Feller S.M., et al. Physiological signals and oncogenesis mediated through Crk family adapter proteins. J. Cell. Physiol. 1998, 177(4):535-552.
23. Feng Y., et al. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res. 2012, 72(24):6502-6511.
24. Fujita Y., et al. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci. Rep. 2013, 3:3325.
25. Gabbasov R., Bickel L., O'Brien S., Litwin S., Seo S., Golemis E., Connolly D. NEDD9 expression promotes epithelial ovarian cancer growth and dissemination. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 2014, 74(19 Suppl.).
26. Giampieri S., et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 2009, 11(11):1287-1296.
27. Gu J.J., et al. Abl family kinases modulate T cell-mediated inflammation and chemokine-induced migration through the adaptor HEF1 and the GTPase Rap1. Sci. Signal. 2012, 5(233):ra51.
28. Guerrero M.S., Parsons J.T., Bouton A.H. Cas and NEDD9 contribute to tumor progression through dynamic regulation of the cytoskeleton. Genes Cancer 2012, 3(5-6):371-381.
29. Guo W., et al. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J. Cell. Biochem. 2013, 114(7):1606-1615.
30. Hammerich-Hille S., et al. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. J. Biol. Chem. 2010, 285(6):3608-3616.
31. Hivert V., Pierre J., Raingeaud J. Phosphorylation of human enhancer of filamentation (HEF1) on serine 369 induces its proteasomal degradation. Biochem. Pharmacol. 2009, 78(8):1017-1025.
32. Hunter A.J., Shimizu Y. Alpha 4 beta 1 integrin-mediated tyrosine phosphorylation in human T cells: characterization of Crk- and Fyn-associated substrates (pp 105, pp115, and human enhancer of filamentation-1) and integrin-dependent activation of p59fyn1. J. Immunol. 1997, 159(10):4806-4814.
33. Ice R.J., et al. NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors. Cancer Res. 2013, 73(10):3168-3180.
34. Iida J., Dorchak J., Clancy R., Slavik J., Ellsworth R., Katagiri Y., Pugacheva E.N., van Kuppevelt T.H., Mural R.J., Cutler M.L., Shriver C.D. Role for chondroitin sulfate glycosaminoglycan in NEDD9-mediated breast cancer cell growth. Exp Cell Res. 2015, 330(2):358-370.
35. Inamoto S., et al. Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7. Oncogene 2007, 26(6):893-904.
36. Ismail H.M. Overexpression of s6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients' survival. J. Oncol. 2012, 2012:416927.
37. Iwata S., Souta-Kuribara A., Yamakawa A., Sasaki T., Shimizu T., Hosono O., Kawasaki H., Tanaka H., Dang N.H., Watanabe T., Arima N., Morimoto C. HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L). Oncogene 2005, 24(7):1262-1271.
38. Izumchenko E., et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 2009, 69(18):7198-7206.
39. Jeang K.T., et al. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J. Biol. Chem. 2004, 279(31):31991-31994.
40. Jin Y., et al. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. Int. J. Cancer 2014, 134(10):2294-2304.
41. Kamiguchi K., et al. Cas-L is required for beta 1 integrin-mediated costimulation in human Tcells. J. Immunol. 1999, 163(2):563-568.
42. Kim M., et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006, 125(7):1269-1281.
43. Kim S.H., et al. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res. 2010, 70(10):4054-4063.
44. Knutson D.C., Clagett-Dame M. A complex RARE is required for the majority of Nedd9 embryonic expression. Transgenic Res. 2015, 24(1):123-134.
45. Kong C., et al. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One 2011, 6(7):e22666.
46. Kondo S., Iwata S., Yamada T., Inoue Y., Ichihara H., Kichikawa Y., Katayose T., Souta-Kuribara A., Yamazaki H., Hosono O., Kawasaki H., Tanaka H., Hayashi Y., Sakamoto M., Kamiya K., Dang N.H., Morimoto C. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer. Clin. Cancer Res. 2012, 18(22):6326-6338.
47. Kozyulina P.Y., Loskutov Y.V., Kozyreva V.K., Rajulapati A., Ice R.J., Jones B.C., Pugacheva E.N. Prometastatic NEDD9 regulates individual cell Migration via caveolin-1-dependent trafficking of integrins. Mol. Cancer Res. 2015, 13(3):423-438.
48. Kumar S., Tomooka Y., Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem. Biophys. Res. Commun. 1992, 185(3):1155-1161.
49. Kumar S., et al. Crk at the quarter century mark: perspectives in signaling and cancer. J. Cell. Biochem. 2014, 115(5):819-825.
50. Law S.F., et al. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol. Cell. Biol. 1996, 16(7):3327-3337.
51. Law S.F., et al. Cell cycle-regulated processing of HEF1 to multiple protein forms differentially targeted to multiple subcellular compartments. Mol. Cell. Biol. 1998, 18(6):3540-3551.
52. Law S.F., et al. The docking protein HEF1 is an apoptotic mediator at focal adhesion sites. Mol. Cell. Biol. 2000, 20(14):5184-5195.
53. Li Y., et al. Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum. Mol. Genet. 2008, 17(5):759-767.
54. Li Y., et al. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene 2011, 30(23):2633-2643.
55. Li L., et al. Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo. J. Cancer Res. Clin. Oncol. 2014, 140(6):895-907.
56. Li P., et al. High expression of NEDD9 predicts adverse outcomes of colorectal cancer patients. Int. J. Clin. Exp. Pathol. 2014, 7(5):2565-2570.
57. Little J.L., et al. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice. Oncogene 2014, 33(4):411-420.
58. Liu X., et al. A novel ability of Smad3 to regulate proteasomal degradation of a Cas family member HEF1. EMBO J. 2000, 19(24):6759-6769.
59. Liu W., et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012, 21(6):751-764.
60. Loskutov Y.V., et al. NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer. Oncogene 2014, 10.1038/onc.2014.297.
61. Lu R., et al. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J. Cancer Res. Clin. Oncol. 2014, 140(3):387-397.
62. Malleter M., et al. A novel large regulator RNA, B2, partially overlaps the HEF1/NEDD9/Cas-L gene. Int. J. Mol. Med. 2010, 25(6):897-903.
63. Manie S.N., et al. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J. Biol. Chem. 1997, 272(7):4230-4236.
64. McLaughlin S.L., et al. NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis. Mol. Cancer Res. 2014, 12(1):69-81.
65. Merrill R.A., et al. All-trans retinoic acid-responsive genes identified in the human SH-SY5Y neuroblastoma cell line and their regulated expression in the nervous system of early embryos. Biol. Chem. 2004, 385(7):605-614.
66. Merrill R.A., et al. Crk-associated substrate (Cas) family member, NEDD9, is regulated in human neuroblastoma cells and in the embryonic hindbrain by all-trans retinoic acid. Dev. Dyn. 2004, 231(3):564-575.
67. Miao Y., et al. Overexpression of NEDD9 is associated with altered expression of E-Cadherin, beta-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer. Pathol. Oncol. Res. 2013, 19(2):281-286.
68. Minegishi M., et al. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes. J. Exp. Med. 1996, 184(4):1365-1375.
69. Minn A.J., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524.
70. Moore F.E., et al. The WW-HECT protein Smurf2 interacts with the Docking Protein NEDD9/HEF1 for Aurora A activation. Cell Div. 2010, 5:22.
71. Morimoto K., et al. NEDD9 crucially regulates TGF-beta-triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: involvement in cancer progressiveness. Prostate 2014, 74(8):901-910.
72. Natarajan M., et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 2006, 25(12):1721-1732.
73. Nikonova A.S., et al. CAS proteins in health and disease: an update. IUBMB Life 2014, 66(6):387-395.
74. Nikonova A.S., et al. Nedd9 restrains renal cystogenesis in Pkd1-/- mice. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(35):12859-12864.
75. Nourry C., et al. Direct interaction between Smad3, APC10, CDH1 and HEF1 in proteasomal degradation of HEF1. BMC Cell Biol. 2004, 5:20.
76. Oda A., et al. CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk. Blood 2001, 97(9):2633-2639.
77. Ohashi Y., et al. T cell receptor-mediated tyrosine phosphorylation of Cas-L, a 105-kDa Crk-associated substrate-related protein, and its association of Crk and C3G. J. Biol. Chem. 1998, 273(11):6446-6451.
78. Ohashi Y., et al. Tyrosine phosphorylation of Crk-associated substrate lymphocyte-type is a critical element in TCR- and beta 1 integrin-induced T lymphocyte migration. J. Immunol. 1999, 163(7):3727-3734.
79. O'Neill G.M., Golemis E.A. Proteolysis of the docking protein HEF1 and implications for focal adhesion dynamics. Mol. Cell. Biol. 2001, 21(15):5094-5108.
80. O'Neill G.M., Fashena S.J., Golemis E.A. Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol. 2000, 10(3):111-119.
81. O'Neill G.M., et al. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007, 67(19):8975-8979.
82. Ota J., et al. Association of CrkL with STAT5 in hematopoietic cells stimulated by granulocyte-macrophage colony-stimulating factor or erythropoietin. Biochem. Biophys. Res. Commun. 1998, 252(3):779-786.
83. Plotnikova O.V., et al. Rapid calcium-dependent activation of Aurora-A kinase. Nat. Commun. 2010, 1:64.
84. Plotnikova O.V., Pugacheva E.N., Golemis E.A. Aurora A kinase activity influences calcium signaling in kidney cells. J. Cell Biol. 2011, 193(6):1021-1032.
85. Plotnikova O.V., et al. Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis. Mol. Biol. Cell 2012, 23(14):2658-2670.
86. Pugacheva E.N., Golemis E.A. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat. Cell Biol. 2005, 7(10):937-946.
87. Pugacheva E.N., Golemis E.A. HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle 2006, 5(4):384-391.
88. Pugacheva E.N., et al. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007, 129(7):1351-1363.
89. Rozenberg G.I., et al. Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res. 2010, 20(5):361-371.
90. Sakakibara A., Hattori S. Chat, a Cas/HEF1-associated adaptor protein that integrates multiple signaling pathways. J. Biol. Chem. 2000, 275(9):6404-6410.
91. Sanchez-Cespedes M., et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002, 62(13):3659-3662.
92. Sanz-Moreno V., et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135(3):510-523.
93. Sasaki T., et al. Nedd9 protein, a Cas-L homologue, is upregulated after transient global ischemia in rats: possible involvement of Nedd9 in the differentiation of neurons after ischemia. Stroke 2005, 36(11):2457-2462.
94. Sattler M., et al. Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J. Biol. Chem. 1997, 272(22):14320-14326.
95. Seo S., et al. Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenance. J. Immunol. 2005, 175(6):3492-3501.
96. Seo S., Ichikawa M., Kurokawa M. Structure and function of cas-L and integrin-mediated signaling. Crit. Rev. Immunol. 2006, 26(5):391-406.
97. Seo S., et al. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl. Cancer Sci. 2011, 102(12):2109-2117.
98. Simpson K.J., et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat. Cell Biol. 2008, 10(9):1027-1038.
99. Singh M., et al. Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem. Biophys. 2007, 48(1):54-72.
100. Singh M.K., et al. Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res. 2010, 70(21):8907-8916.
101. Speranza M.C., et al. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget 2012, 3(7):723-734.
102. Stajduhar E., et al. Expression of growth hormone receptor, plakoglobin and NEDD9 protein in association with tumour progression and metastasis in human breast cancer. Tumour Biol. 2014, 35(7):6425-6434.
103. Tachibana K., Urano T., Fujita H., Ohashi Y., Kamiguchi K., Iwata S., Hirai H., Morimoto C. Tyrosine phosphorylation of Crk-associated substrates by focal adhesion kinase. A putative mechanism for the integrin-mediated tyrosine phosphorylation of Crk-associated substrates. J. Biol. Chem. 1997, 272(46):29083-29090.
104. Tedde A., et al. Different implication of NEDD9 genetic variant in early and late-onset Alzheimer's disease. Neurosci. Lett. 2010, 477(3):121-123.
105. Thao le B., et al. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol. Ther. 2009, 8(8):683-688.
106. Tikhmyanova N., Golemis E.A. NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One 2011, 6(7):e22102.
107. Tikhmyanova N., Little J.L., Golemis E.A. CAS proteins in normal and pathological cell growth control. Cell. Mol. Life Sci. 2010, 67(7):1025-1048.
108. Titz B., et al. The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene 2010, 29(44):5895-5910.
109. Torres V.E., Harris P.C. Autosomal dominant polycystic kidney disease: the last 3years. Kidney Int. 2009, 76(2):149-168.
110. van Seventer G.A., et al. Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway. Eur. J. Immunol. 2001, 31(5):1417-1427.
111. Wallez Y., et al. NSP-CAS protein complexes: emerging signaling modules in cancer. Genes Cancer 2012, 3(5-6):382-393.
112. Wang Y., et al. NEDD9 rs760678 polymorphism and the risk of Alzheimer's disease: a meta-analysis. Neurosci. Lett. 2012, 527(2):121-125.
113. Wang H., et al. NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer. Hum. Pathol. 2014, 45(2):401-408.
114. Xia D., et al. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res. 2010, 70(2):824-831.
115. Xia L., et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 2013, 57(2):610-624.
116. Xing Y.Y., et al. NEDD9 is genetically associated with Alzheimer's disease in a Han Chinese population. Brain Res. 2011, 1369:230-234.
117. Xue Y.Z., et al. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol. 2013, 34(2):895-899.
118. Zheng M., McKeown-Longo P.J. Regulation of HEF1 expression and phosphorylation by TGF-beta 1 and cell adhesion. J. Biol. Chem. 2002, 277(42):39599-39608.
119. Zheng M., McKeown-Longo P.J. Cell adhesion regulates Ser/Thr phosphorylation and proteasomal degradation of HEF1. J. Cell Sci. 2006, 119(Pt 1):96-103.
120. Zhong J., et al. NEDD9 regulates 3D migratory activity independent of the Rac1 morphology switch in glioma and neuroblastoma. Mol. Cancer Res. 2014, 12(2):264-273.